Ipsen (LTS:0MH6) FFO


LTS:0MH6 Ipsen SA LTS:0MH6
95 GF Score
Price €162.45
GF Value €133.49
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0MH6
95GF Score
Ipsen SA LTS:0MH6
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (LTS:0MH6) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €162.45 is trading 21.7% above its estimated GF Value™ of €133.49. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for LTS:0MH6:

  • FFO:
  • GF Value™: €133.49 vs. price of €162.45 (21.7% above fair value)
  • GF Score™: 95/100 with 7 warning signs

No single metric tells the full story. See the LTS:0MH6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
95GF Score

Get the complete analysis for LTS:0MH6

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€162.45
Price
€133.49
GF Value